Tyrosine Pharma, Inc.
Every 40 seconds someone in the US suffers from stroke. Tyrosine Pharma is in development of a therapeutic treatment to reduce brain damage.
Dr. Surojit Paul, the product's inventor, has developed a method and formula to generate a cell-permeable STEP peptide that can bind constitutively to its substrates and is resistant to degradation. Preliminary studies have indicated that intravenous injection of the cell-permeable STEP peptide either before or after an acute ischemic stroke can provide significant protection against ischemic brain injury.